An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35394532.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0341 and PMC identifier 9197849.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Central Nervous System Neoplasms
- Lung Neoplasms